# Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

> **NCT02457273** · PHASE2 · COMPLETED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 23 (actual)

## Conditions studied

- Neuroendocrine Carcinomas

## Interventions

- **DRUG:** TLC 388

## Key facts

- **NCT ID:** NCT02457273
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-04
- **Primary completion:** 2018-04-18
- **Final completion:** 2018-12-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-04-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02457273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02457273, "Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02457273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*